Какие схемы лечения инфекции Helicobacter pylori нужны нам сегодня?


Маев И.В., Кучерявый Ю.А., Оганесян Т.С., Баркалова Е.В.

Кафедра пропедевтики внутренних болезней и гастроэнтерологии ГОУ ВПО МГМСУ Минздравсоцразвития России, Москва
Тройная терапия первой линии, несмотря на ее снижающуюся эффективность, что обусловлено растущей резистентностью к кларитромицину и метронидазолу, остается терапией выбора для первичного лечения больных, инфицированных Helicobacter pylori. Путем повышения эффективности 7-дневных схем первой линии с кларитромицином является применение современных и более эффективных ингибиторов протонной помпы (ИПП), таких как эзомепразол, обеспечивающих 5–10 %-ное преимущество над ИПП первых генераций (неизомеров). В качестве терапии резерва в России могут быть использованы последовательная (стандартная или модифицированная) терапия, схемы с амоксициллином, препаратами висмута и фуразолидоном, если это будет регламентировано национальными рекомендациями.

Литература


1. Маев И.В., Кучерявый Ю.А., Оганесян Т.С. Аллельный полиморфизм интерлейкина1β при геликобактериозе // Росс. журн. гастроэнтерол., гепатол., колопроктол. 2008. № 5. С. 4–11.


2. Anagnostopoulos GK, Tsiakos S, Margantinis G, et al. Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study. J Clin Gastroenterol 2004;38(6):503–506.


3. Andersson T, Hassan-Alin M, Hasselgren G, et al. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001;40(7):523–37.


4. Buzas GM. First-line eradication of Helicobacter pylori: are the standard triple therapies obsolete? A different perspective. World J Gastroenterol 2010;16(31):3865–70.


5. Caselli M, Zullo A, Maconi G, et al. Cervia II Working Group Report 2006”: guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis 2007; 39:782–89.


6. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808–25.


7. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010;19(4):409–14.


8. Erah PO, Goddard AF, Barrett DA, et al. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 1997;39(1):5–12.


9. Essa AS, Kramer JR, Graham DY, et al. Metaanalysis: four-drug, three-antibiotic, nonbismuthcontaining “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009; 14(2):109–18.


10. Fischbach LA, Goodman KJ, Feldman M, et al. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int J Epidemiol 2002; 31:128–39.


11. Fuccio L, Minardi ME, Zagari RM, et al. Meta-analysis: duration of first-line protonpump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147(8):553–62.


12. Gatta L, Vakil N, Leandro G, et al. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and metaanalysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009;104(12):3069–79.


13. Giannini EG, Bilardi C, Dulbecco P, et al. Can Helicobacter pylori eradication regimens be shortened in clinical practice? An openlabel, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole. J Clin Gastroenterol 2006;40:515–20.


14. Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterol 1998;115:1272–77.


15. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275–78.


16. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008;5(6):321–31.


17. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59(8):1143–53.


18. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/UCM184500.pdf


19. Lambert JR, Midolo P. The actions of bismuth in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997;11(1):27–33.


20. Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56(6):772–81.


21. Malfertheiner P, Selgrad M. Helicobacter pylori infection and current clinical areas of contention. Curr Opin Gastroenterol 2010;26(6):618–23.


22. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374–784.


23. Megraud F, Lehours P. Helicobacter pylori detection and иantimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20:280–322.


24. Scaccianoce G, Hassan C, Panarese A, et al. Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen. Can J Gastroenterol 2006;20(2):113–17.


25. Scott D, Weeks D, Melchers K, et al. The life and death of Helicobacter pylori. Gut 1998;43(1):56–60.


26. Sheu BS, Kao AW, Cheng HC, et al. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment Pharmacol Ther2005; 21(3):283–88.


27. Sugimoto M, Furuta T, Shirai N, et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 2007;12(4):317–23.


28. Vallve M, Vergara M, Gisbert JP, et al. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther 2002;16(6):1149–156.


29. Villoria A, Garcia P, Calvet X, et al. Metaanalysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008;28(7):868–77.


30. Wang X, Fang JY, Lu R, et al A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori. Digestion 2006;73(2–3):178–86.


31. Zullo A, De Francesco V, Hassan C, et al. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007;56(10):1353–357.


Похожие статьи


Бионика Медиа